Download PDFPDF

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    The potential effect of dichotomising age (a continuous variable) in multivariate model analysis
    • Abebaw M Yohannes, Senior Lecturer
    • Other Contributors:
      • Connolly MJ, Senior Lecturer, University of Manchester

    Dear Editor

    We have read with great interest, Soler-Catauna and colleagues [1] article that examined, in an impressive prospective study with five years follow-up, factors predicting poor prognosis and mortality in patients with severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Their findings are complimentary with the current available literature in identifying that older age, arteri...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and dis

    Dear Editor,

    The above guidelines will prove useful to rheumatologists or gastroenterologists who will be prescribing these revolutionary drugs for their patients. I, however, have difficulty with algorithm of figure where tuberculin testing comes before risk stratification. For patients with normal chest x-rays and a low risk stratification it will not really matter if their tuberculin test is positive or negativ...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Comments and queries

    Dear Editor,

    Thanks to all concerned for putting together a very useful and long awaited guideline. I have the following questions and comments.

    1. What does "All Patient Rate" in table 3B mean and when should one use it, if at all for UK born patients (say white) as opposed to table 3A?

    Does a UK born white of 75 have a risk of 11 (Table 3A) or 4 (Table 3B - All patient rate column)?

    2. I...

    Show More
    Conflict of Interest:
    None declared.